论文信息 - U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors - 字舞流文

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

P. Jänne | Qinying Zhao | H. Wakelee | A. Shaw | S. Ou | Ryohei Katayama | K. Papadopoulos | G. Senaldi | R. Madison | H. Hanzawa | T. Seto | A. Schrock | E. Borazanci | T. Sun | T. Isoyama | Masaya Tachibana | V. Zhu | K. Nakamaru | Yanfei Gao | C. Deng | Yuki Shimizu | N. Nakao | Frank Fan | Meijing Li